Diabetes
Refine Search
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Biotechnology
The past year has been a very busy one for privately-held Dewpoint Therapeutics, a Boston firm founded in 2018 that focuses on the application of biomolecular condensate biology towards the development of a new generation of therapeutics to address diseases of high unmet need. 7 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
UK pharma giant GlaxoSmithKline plc (LSE: GSK) says that top-line results have been received from seven of the eight Harmony Phase III studies investigating the use of albiglutide in type 2 diabetes, which it believes support progression toward regulatory filing of the product. 3 April 2012
Pharmaceutical
The US Food and Drug Administration has approved Levemir (insulin detemir [rDNA origin] injection), from Danish insulin giant Novo Nordisk (NOV: N) for a pregnancy Category B classification, indicating that Levemir, when used in pregnant women with diabetes, did not increase the risk of harm to the unborn baby. 2 April 2012
Pharmaceutical
Scientists from the Florida, USA, campus of The Scripps Research Institute have synthesized a pair of small molecules that dramatically alter the core biological clock in animal models, highlighting the potential effectiveness of these compounds in treating a remarkable range of disorders - including obesity, diabetes, high cholesterol and serious sleep disorders. The study was published on March 29, 2012, in an advance, on-line edition of the journal Nature. 1 April 2012
Pharmaceutical
US drug developer Targacept (Nasdaq: TRGT) saw its shares drop 5% to $5.12 ,after the company announced mixed results of its Phase II studies with TC-6987, and announcing its decision to drop development of the products as a treatment for diabetes. 28 March 2012
Biotechnology
New York. USA-based biotech company Islet Sciences (OTC.BB: ISLT),said Friday that it has closed its previously-announced stock acquisition of DiaKine Therapeutics, a biopharmaceutical company developing new, proprietary drugs for unmet medical needs in diabetes and complications related to diabetes. 26 March 2012
Pharmaceutical
US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) and drug major Eli Lilly (NYSE: LLY) said on Friday that the European Commission has granted marketing authorization for their Byetta (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents. 26 March 2012
Pharmaceutical
Colorado, USA-based biopharma firm Ampio Pharmaceuticals,(Nasdaq: AMPE) yesterday announced that it completed the planned interim review of the first 50% of patients enrolled in the trial of Optina, an orally administered ultra low dose of danazol, for the treatment of diabetic macular edema with positive findings. 20 March 2012
Pharmaceutical
There is a wide gender divide when it comes to how men and women in the USA are prescribed and adhere to their medications. According to a new study, while women use more prescription drugs than men, they are less likely to be prescribed drugs according to clinical guidelines and are not as good about adhering to the medications they are prescribed. 19 March 2012
Biotechnology
Indian biotech firm Biocon (BSE: 532523) and global drugs behemoth Pfizer (NYSE: PFE) yesterday announced that they have called off their alliance to commercialize Biocon's biosimilar versions of Insulin and Insulin analog products, Recombinant Human Insulin, Glargine, Aspart and Lispro. 14 March 2012
Pharmaceutical
US therapeutic antibody discovery firm XOMA Corp (Nasdaq: XOMA) announced that results from a study of XMetA, the company's fully-human allosteric monoclonal antibody to the insulin receptor, confirmed by investigators at the University of California, San Francisco, demonstrate that XMetA has the potential to be a novel, long-acting agent for the control of blood glucose levels in patients with diabetes. 12 March 2012
Pharmaceutical
The US Food and Drug Administration (FDA) has sent a warning letter to Merck & Co for failing to carry out a post-marketing study which was a condition for approval of Januvia (sitagliptin) and Janumet (sitagliptin and metformin). 28 February 2012
Pharmaceutical
A Phase II trial of Takeda's GPR40 agonist TAK-875 published in The Lancet has found that the drug is effective in patients with type 2 diabetes. 28 February 2012
Pharmaceutical
The UK's health care guidance body the National Institute for Health and Clinical Excellence (NICE), has today confirmed its initial draft and final draft positive recommendation of US drug major Eli Lilly and biotech firm Amylin's (Nasdaq: AMLN) Bydureon (exenatide, prolonged release). 22 February 2012
Biotechnology
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on Friday issued a positive opinion for US health care major Abbott Laboratories' (NYSE: ABT) blockbuster rheumatoid and psoriatic arthritis drug Humira (adalimumab), for use in adults with moderate to severely active ulcerative colitis (UC) who have not responded to, cannot tolerate or have medical contraindications to conventional therapies. 20 February 2012
Pharmaceutical
Danish peptide drug discovery firm Zealand Pharma (Nasdaq OMX Copenhagen: ZEAL) says it will receive a milestone payment of $20 million from French drug major Sanofi (Euronext: SAN) following the successful completion of the global GetGoal Phase III clinical trial program for lixisenatide (proposed trade name Lyxumia). 13 February 2012
Biotechnology
US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN) reported that in loss for the fourth quarter of 2011 leapt to $461.5 million, or $3.15 a share on a GAAP basis, up from $19.2 million, or $0.13 per share in the like year ago quarter. 7 February 2012
Biotechnology
French biotech firm Genfit (Alternext: ALGFT) says that its leading drug candidate GFT505 in a Phase II clinical study dubbed GFT505-210-6 has reached all its primary and secondary efficacy objectives with no adverse side effects. 5 February 2012
Pharmaceutical
Danish insulin giant Novo Nordisk (NVO: N) yesterday reported full-year 2011 sales of 66.35 billion Danish kroner ($11.72 billion), which increased by 11% in local currencies and 9% in Danish kroner, driven by modern insulins at and its novel type 2 diabetes drug Victoza (liraglutide). The company's shares rose nearly 5% to 713 kroner in Copenhagen after the release of the earnings report, as the results beat analysts' expectations. 3 February 2012
Pharmaceutical
The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin and metformin, developed by German family-owned drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) for the treatment of type 2 diabetes. The news lifted Lilly's shares by 1.2% to $39.70 in late trading on Monday. 1 February 2012
Generics
Icelandic generics drugmaker Actavis and Poland's Bioton (WSE: BIO) have formed a joint venture company for the development and registration of insulins, including analogue insulins, aiming to shake up the diabetes market. 31 January 2012
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze